Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration

Sarah S P DiMagno¹, Aaron Glickman¹, Ezekiel J Emanuel^{1

2}

Affiliations

¹ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Health Care Management, The Wharton School, University of Pennsylvania, Philadelphia.

Comment

Sarah S P DiMagno et al. JAMA Intern Med. 2019.

. 2019 Jul 1;179(7):922-923.

doi: 10.1001/jamainternmed.2019.0584.

Sarah S P DiMagno¹, Aaron Glickman¹, Ezekiel J Emanuel^{1

2}

¹ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
² Department of Health Care Management, The Wharton School, University of Pennsylvania, Philadelphia.

No abstract available

Comment on

Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.
Gyawali B, Hey SP, Kesselheim AS. Gyawali B, et al. JAMA Intern Med. 2019 Jul 1;179(7):906-913. doi: 10.1001/jamainternmed.2019.0462. JAMA Intern Med. 2019. PMID: 31135808 Free PMC article. Review.
An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY, Raghunathan V, Prasad V. Chen EY, et al. JAMA Intern Med. 2019 Jul 1;179(7):915-921. doi: 10.1001/jamainternmed.2019.0583. JAMA Intern Med. 2019. PMID: 31135822 Free PMC article. Review.